Viral Vectors and Plasmid DNA Manufacturing Powering the Gene Therapy Revolution
Viral vectors and plasmid DNA manufacturing have become foundational pillars of modern biotechnology, enabling the rapid advancement of gene and cell therapies, genetic vaccines, and next-generation biologics. As precision medicine moves from experimental stages into clinical and commercial reality, the demand for scalable, high-quality, and compliant manufacturing platforms continues to accelerate. Today’s industry evolution is defined by four major forces: the expansion of gene and cell therapy pipelines, diversification of viral vector types, a strong focus on cGMP-grade plasmid DNA production, and the rise of strategic collaborations with contract development and manufacturing organizations (CDMOs). Expansion of Gene and Cell Therapy Pipelines The global pipeline of gene and cell therapies has expanded dramatically over the past decade. Therapies targeting rare genetic disorders, oncology, neurological diseases, and inherited metabolic conditions are progressing...